Aripiprazole as an Inhibitor of the EGFR/PI3K/AKT Signaling Pathway and Sensitizer of MPA Suppressed Progestin‐Resistant Endometrial Cancer Cells
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.70017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Wen Gan und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioreactor Engineering, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Frontiers Science Ce…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Aripiprazole, Medroxyprogesterone Acetate, Antineoplastic Agents. Die Arbeit nennt 38 Literaturangaben. Gefördert von: This study was supported by the National Natural Science Foundation of China (22477028, 32121005), National key R&D Program of China (2021YFA0804904), Shanghai….
Abstract (Originalsprache)
Drug repurposing, which involves applying existing pharmaceuticals to new therapeutic areas, offers several advantages, including increased efficiency, reduced costs, and lower risks. The research aimed to investigate the molecular mechanisms underlying the new application of the antipsychotic drug aripiprazole (APZ) in the treatment of endometrial cancer (EC), as well as its synergistic efficacy when used in combination with progestin. The cell viability assay and proliferation assay demonstrated that APZ exerted a significant inhibitory effect on the proliferation of ISK and KLE cells. Moreover, APZ was found to induce cell apoptosis prominently by flow cytometry. Network pharmacology analysis indicated that the anti‐EC effects of APZ were mediated via the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3‐kinase (PI3K)/protein kinase B (AKT) signaling pathway, which was subsequently confirmed by Western blot analysis. Furthermore, APZ significantly enhanced the proliferation inhibitory effect of medroxyprogesterone acetate (MPA) against progestin‐resistant KLE cells, displaying remarkable synergistic activity. These findings position APZ as a promising therapeutic candidate for EC, with potential utility both as a monotherapy and in combination with MPA, offering new avenues for EC treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioreactor Engineering, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Frontiers Science Center for Materiobiology and Dynamic Chemistry, Shanghai Key Laboratory…
- Department of Gynecologic Oncology, the International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, School of Pharmacy, Shihezi University, Shihezi, China.
- Key Laboratory of Tropical Biological Resources of Ministry of Education, College of Pharmacy, Hainan University, Haikou, China.
ORCID-Profile: Fei Mao
Förderung
- This study was supported by the National Natural Science Foundation of China (22477028, 32121005), National key R&D Program of China (2021YFA0804904), Shanghai…
Zitieren
APA
Gan, W., Liu, X., Zhou, Y., Gu, W., Liu, X., Song, L., Li, J., Wang, Y., & Mao, F. (2025). Aripiprazole as an Inhibitor of the EGFR/PI3K/AKT Signaling Pathway and Sensitizer of MPA Suppressed Progestin‐Resistant Endometrial Cancer Cells. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70017
Vancouver
Gan W, Liu X, Zhou Y, Gu W, Liu X, Song L, et al. Aripiprazole as an Inhibitor of the EGFR/PI3K/AKT Signaling Pathway and Sensitizer of MPA Suppressed Progestin‐Resistant Endometrial Cancer Cells. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70017
BibTeX
@article{Gan2025,
author = {Gan, Wen and Liu, Xinyu and Zhou, Yikang and Gu, Wei and Liu, Xiaohu and Song, Lingyi and Li, Jian and Wang, Yudong and Mao, Fei},
title = {Aripiprazole as an Inhibitor of the EGFR/PI3K/AKT Signaling Pathway and Sensitizer of MPA Suppressed Progestin‐Resistant Endometrial Cancer Cells},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.70017}
}
EUVIMED